Literature DB >> 16142397

Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.

Makoto Nakamuta1, Motoyuki Kohjima, Shusuke Morizono, Kazuhiro Kotoh, Tsuyoshi Yoshimoto, Izuru Miyagi, Munechika Enjoji.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent causes of abnormal liver dysfunction, and its prevalence has markedly increased; however, the mechanisms involved in the pathogenesis of NAFLD have not been thoroughly investigated in humans. In this study, we evaluated the expression of fatty acid metabolism-related genes in NAFLD. Real-time RT-PCR was performed using liver biopsy samples from 12 NAFLD patients. The target genes studied were: acetyl-CoA carboxylase (ACC) 1, ACC2, and fatty acid synthase (FAS) for the evaluation of de novo fatty acid synthesis; carnitine palmitoyltransferase 1a (CPT1a), long-chain acyl-CoA dehydrogenase (LCAD), and long-chain L-3-hydroxyacyl-coenzyme A dehydrogenase alpha (HADHalpha) for beta-oxidation in the mitochondria; peroxisome proliferator-activated receptor- (PPAR-) alpha and cytochrome P450 2E1 (CYP2E1) for oxidation in peroxisomes and microsomes (endoplasmic reticulum) respectively; and diacylglycerol O-acyltransferase 1 (DGAT1), PPAR-gamma, and hormone sensitive lipase (HSL) for triglyceride synthesis and catalysis. In NAFLD, expression of ACC1 and ACC2, but not FAS was increased, indicating that de novo fatty acid synthesis is enhanced in NAFLD. In contrast, expression of CTP1a, a rate-limiting enzyme, was remarkably decreased, indicating that beta-oxidation in the mitochondria was decreased, although the expression of LCAD and HADHalpha was increased. Expression of PPAR-alpha was increased, whereas that of CYP2E1 was reduced. The expression of DGAT1, PPAR-gamma, and HSL was enhanced. These data suggest that in NAFLD, increased de novo synthesis and decreased beta-oxidation in the mitochondria lead to accumulation of fatty acids in hepatocytes, although the extent of oxidation in peroxisomes and microsomes remains unclear.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16142397

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  43 in total

Review 1.  Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?

Authors:  Munechika Enjoji; Makoto Nakamuta
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

Review 2.  Mitochondrial fatty acid oxidation in obesity.

Authors:  Dolors Serra; Paula Mera; Maria Ida Malandrino; Joan Francesc Mir; Laura Herrero
Journal:  Antioxid Redox Signal       Date:  2012-10-05       Impact factor: 8.401

3.  A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits.

Authors:  Tomohiro Ogawa; Hideki Fujii; Katsutoshi Yoshizato; Norifumi Kawada
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

Review 4.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

Review 5.  Mitochondria and redox signaling in steatohepatitis.

Authors:  E Matthew Morris; R Scott Rector; John P Thyfault; Jamal A Ibdah
Journal:  Antioxid Redox Signal       Date:  2011-04-26       Impact factor: 8.401

Review 6.  Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature.

Authors:  Masafumi Ono; Toshiji Saibara
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

Review 7.  Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation.

Authors:  Amanda Karolina Soares Silva; Christina Alves Peixoto
Journal:  Cell Mol Life Sci       Date:  2018-05-22       Impact factor: 9.261

8.  NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.

Authors:  Munechika Enjoji; Kazuyuki Machida; Motoyuki Kohjima; Masaki Kato; Kazuhiro Kotoh; Kazuhisa Matsunaga; Manabu Nakashima; Makoto Nakamuta
Journal:  Lipids Health Dis       Date:  2010-03-12       Impact factor: 3.876

Review 9.  Molecular mechanisms involved in NAFLD progression.

Authors:  Mariano Malaguarnera; Michelino Di Rosa; Ferdinando Nicoletti; Lucia Malaguarnera
Journal:  J Mol Med (Berl)       Date:  2009-04-08       Impact factor: 4.599

10.  Increased expression of c-Jun in nonalcoholic fatty liver disease.

Authors:  Christoph Dorn; Julia C Engelmann; Michael Saugspier; Andreas Koch; Arndt Hartmann; Martina Müller; Rainer Spang; Anja Bosserhoff; Claus Hellerbrand
Journal:  Lab Invest       Date:  2014-02-03       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.